CN108699083A - 喹啉酮类似物及其盐的结晶形式 - Google Patents

喹啉酮类似物及其盐的结晶形式 Download PDF

Info

Publication number
CN108699083A
CN108699083A CN201580085777.5A CN201580085777A CN108699083A CN 108699083 A CN108699083 A CN 108699083A CN 201580085777 A CN201580085777 A CN 201580085777A CN 108699083 A CN108699083 A CN 108699083A
Authority
CN
China
Prior art keywords
crystal form
cancer
compound
peak
shows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580085777.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·M·瑞克曼
I·G·于
H-T·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of CN108699083A publication Critical patent/CN108699083A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580085777.5A 2015-12-14 2015-12-14 喹啉酮类似物及其盐的结晶形式 Pending CN108699083A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/065443 WO2017105382A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Publications (1)

Publication Number Publication Date
CN108699083A true CN108699083A (zh) 2018-10-23

Family

ID=59057173

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580085777.5A Pending CN108699083A (zh) 2015-12-14 2015-12-14 喹啉酮类似物及其盐的结晶形式

Country Status (10)

Country Link
EP (2) EP4249072A3 (https=)
JP (1) JP2018537486A (https=)
KR (1) KR20180111797A (https=)
CN (1) CN108699083A (https=)
AU (2) AU2015417382A1 (https=)
CA (2) CA3006502A1 (https=)
ES (1) ES2959536T3 (https=)
IL (1) IL260004A (https=)
RU (1) RU2018124599A (https=)
WO (1) WO2017105382A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222147A1 (zh) * 2023-04-23 2024-10-31 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334133A (zh) * 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
CA3129722A1 (en) * 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
CA3151116A1 (en) * 2019-08-14 2021-02-18 Hshiou-Ting Liu Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
EP4013421A4 (en) * 2019-08-14 2023-08-23 Senhwa Biosciences, Inc. TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022474A2 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
CN101888780A (zh) * 2007-10-05 2010-11-17 赛林药物股份有限公司 喹诺酮类似物及其相关方法
CN103533934A (zh) * 2011-03-17 2014-01-22 特尔汗什莫尔医学基础设施研究和服务公司 用于治疗自身免疫性疾病的喹诺酮类似物
WO2015079411A1 (en) * 2013-11-28 2015-06-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034113A2 (en) * 2004-09-17 2006-03-30 Cylene Pharmaceuticals, Inc. Quinolone analogs as cell proliferation inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022474A2 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
CN101888780A (zh) * 2007-10-05 2010-11-17 赛林药物股份有限公司 喹诺酮类似物及其相关方法
CN103533934A (zh) * 2011-03-17 2014-01-22 特尔汗什莫尔医学基础设施研究和服务公司 用于治疗自身免疫性疾病的喹诺酮类似物
WO2015079411A1 (en) * 2013-11-28 2015-06-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DENIS DRYGIN ET AL.: ""Targeting the nucleolus for cancer-specific activation of p53"", 《DRUG DISCOVERY TODAY》 *
JACLYN E. QUIN ET AL.: ""Targeting the nucleolus for cancer intervention"", 《BIOCHIMICA ET BIOPHYSICA ACTA》 *
MICHAEL K. SCHWAEBE ET AL.: ""Facile and efficient generation of quinolone amides from esters using aluminum chloride"", 《TETRAHEDRON LETTERS》 *
MUSTAPHA HADDACH ET AL.: ""Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics"", 《ACS MEDICINAL CHEMISTRY LETTERS》 *
吕扬 等: "《晶型药物》", 31 October 2009, 人民卫生出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222147A1 (zh) * 2023-04-23 2024-10-31 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途

Also Published As

Publication number Publication date
JP2018537486A (ja) 2018-12-20
EP3394070A1 (en) 2018-10-31
AU2021203085A1 (en) 2021-06-10
EP3394070B1 (en) 2023-08-02
EP4249072A2 (en) 2023-09-27
IL260004A (en) 2018-07-31
EP3394070A4 (en) 2019-05-08
AU2015417382A1 (en) 2018-06-14
ES2959536T3 (es) 2024-02-26
AU2021203085B2 (en) 2023-06-08
EP4249072A3 (en) 2023-10-25
CA3255938A1 (en) 2025-11-28
RU2018124599A (ru) 2020-01-16
KR20180111797A (ko) 2018-10-11
CA3006502A1 (en) 2017-06-22
EP3394070C0 (en) 2023-08-02
WO2017105382A1 (en) 2017-06-22
RU2018124599A3 (https=) 2020-01-16

Similar Documents

Publication Publication Date Title
AU2021203085B2 (en) Crystalline forms of quinolone analogs and their salts
US9957282B2 (en) Crystalline forms of quinolone analogs and their salts
JP6657294B2 (ja) ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
JP2020533412A (ja) ２−（５−（４−（２−モルホリノエトキシ）フェニル）ピリジン−２−イル）−ｎ−ベンジルアセトアミドの固体形態
CN104995180A (zh) 神经营养因子模拟化合物及其盐的结晶形式
JP2022179783A (ja) キノロン類似体及びその塩の結晶形
TW202115091A (zh) 喹啉類似物之結晶型及其鹽類、組合物、及彼等之使用方法
JP2019518062A (ja) Ｎ−（２−（２−（ジメチルアミノ）エトキシ）−４−メトキシ−５−（（４−（１−メチル−１ｈ−インドール−３−イル）ピリミジン−２−イル）アミノ）フェニル）アクリルアミドの薬学的塩およびそれらの結晶形
CN105753869B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
TWI765848B (zh) 喹諾酮類似物及其鹽的結晶形式
HK40098923A (en) Crystalline forms of quinolone analogs and their salts
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
JP2022509701A (ja) コリダルミンの結晶性塩
HK1262794B (en) Crystalline forms of quinolone analogs and their salts
HK1262794A1 (en) Crystalline forms of quinolone analogs and their salts
WO2024064690A1 (en) Erk1/2 inhibitor polymorph forms
HK40120176A (zh) 尼拉帕利盐
WO2016050016A1 (zh) 作为激酶抑制剂的取代杂环化合物及其制备方法和用途
CN116887818A (zh) 口服固体剂量制剂
HK1212970B (en) Crystalline forms of neurotrophin mimetic compounds and their salts
HK1177152A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
HK1177152B (en) Crystalline forms of neurotrophin mimetic compounds and their salts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181023

RJ01 Rejection of invention patent application after publication